The Journal of Urology
Volume 182, Issue 2 , Pages 491-498 , August 2009

Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy

  • Lionel L. Bañez

      Affiliations

    • Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
    • Urology Section, Veterans Affairs Medical Center, Durham, North Carolina
    • Corresponding Author InformationCorrespondence: Division of Urologic Surgery and Duke Prostate Center, and Department of Surgery, Duke University Medical Center, Box 2626, MSRB-I, Suite 455, 571 Research Dr., Durham, North Carolina 27710 (telephone: 919-668-8449; FAX: 919-668-7093)
    • Financial interest and/or other relationship with AstraZeneca.
    • ,
  • Leon Sun

      Affiliations

    • Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
    • ,
  • Bruce J. Trock

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
    • ,
  • Misop Han

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
    • ,
  • Alan W. Partin

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
    • ,
  • William J. Aronson

      Affiliations

    • Urology Section, Veterans Affairs Greater Los Angeles Healthcare System and Department of Urology, University of California Los Angeles School of Medicine, Los Angeles, California
    • ,
  • Martha K. Terris

      Affiliations

    • Urology Section, Veterans Affairs Medical Center, Augusta and Section of Urology, Medical College of Georgia, Augusta, Alabama
    • ,
  • Joseph C. Presti Jr

      Affiliations

    • Urology Section, Veterans Affairs Medical Center and Department of Urology, Stanford University School of Medicine, Palo Alto, California
    • ,
  • Christopher J. Kane

      Affiliations

    • Urology Section, Veterans Affairs Medical Center, San Diego and Department of Urology, University of California San Diego, San Diego, California
    • ,
  • Christopher L. Amling

      Affiliations

    • Urology Section, Veterans Affairs Medical Center, and Department of Urology, University of Alabama, Birmingham, Alabama
    • ,
  • Judd W. Moul

      Affiliations

    • Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
    • Financial interest and/or other relationship with Sanofi-Aventis, AstraZeneca and GlaxoSmithKline.
    • ,
  • Stephen J. Freedland

      Affiliations

    • Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
    • Department of Pathology, Duke University Medical Center, Durham, North Carolina
    • Urology Section, Veterans Affairs Medical Center, Durham, North Carolina

Received 19 November 2008

References 

  1. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110
  2. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005;174:919
  3. Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008;26:835
  4. Connolly D, Black A, Gavin A, et al. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev. 2008;17:271
  5. Amling CL, Kane CJ, Riffenburgh RH, et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001;58:723
  6. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446
  7. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:63
  8. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med. 2003;348:1625
  9. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005;103:1092
  10. Barqawi AB, Golden BK, O'Donnell C, et al. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology. 2005;65:708
  11. Gray MA, Delahunt B, Fowles JR, et al. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res. 2004;24:2069
  12. Ku JH, Kim ME, Lee NK, et al. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology. 2003;61:132
  13. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in U. S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev. 2007;16:70
  14. Fowke JH, Motley SS, Cookson MS, et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2007;10:137
  15. Bañez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298:2275
  16. Price MM, Hamilton RJ, Robertson CN, et al. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008;71:787
  17. Rundle A, Neugut AI. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate. 2008;68:373
  18. Ando R, Nagaya T, Hashimoto Y, et al. Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004–2006. Urology. 2008;72:561
  19. Harrell FE, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA. 1982;247:2543
  20. Department of Health and Human Services Centers for Disease Control and Prevention. Overweight and Obesity: U. S. Obesity Trends 1985–2007, vol 2008. http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htmAccessed November 22, 2008.
  21. Freedland SJ, Terris MK, Platz EA, et al. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology. 2005;66:108
  22. Freedland SJ, Isaacs WB, Mangold LA, et al. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res. 2005;11:2883
  23. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766
  24. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969
  25. Schroeck FR, Sun L, Freedland SJ, et al. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008;11:371
  26. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128
  27. Freedland SJ, Humphreys EB, Mangold LA, et al. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol. 2006;176:1404

 Study received institutional review board approval at each institution.

 Supported by the Department of Defense Prostate Cancer Research Program, Department of Veterans Affairs, Duke University Department of Surgery and Division of Urology, an American Urological Association Foundation/Astellas Rising Star in Urology Award, National Institutes of Health Specialized Programs of Research Excellence Grants P50 CA58236 and P50 CA92131-01A1, Georgia Cancer Coalition and National Institutes of Health R01CA100938.

PII: S0022-5347(09)00892-1

doi: 10.1016/j.juro.2009.04.007

The Journal of Urology
Volume 182, Issue 2 , Pages 491-498 , August 2009

Article Tools